SOPHiA GENETICS announced a multi-year collaboration with AstraZeneca to develop and commercialize two companion diagnostics supporting precision oncology therapies. The partnership will focus on creating decentralized diagnostics for solid tumors and blood cancers, enabling local labs worldwide to perform standardized tests from day one of drug approval. This effort aims to improve patient access to targeted treatments by combining AI-driven biomarker detection with rapid deployment through SOPHiA GENETICS's global data platform. The collaboration supports advancing precision medicine by connecting healthcare institutions globally to enhance clinical decision-making and patient outcomes.
The FTSE 100 fell 30 points to 10,838, dragged down by AstraZeneca's 9.3% drop following reports of merger talks with Bristol Myers Squibb, which raised concerns over strategic fit and antitrust issues. Commodity giants like Rio Tinto and BP also dec...
AIM ImmunoTech announced that the final patient has received their last dose in the Phase 2 DURIPANC trial testing Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer, ahead of schedule. The primary endpoint analysis will st...
Wall Street is expected to start August mostly higher with Dow Jones futures up 1% and S&P 500 gaining 0.5%, while Nasdaq futures remain flat following a recent tech rebound. Last month, technology stocks struggled, notably the Philadelphia Semicondu...
The FTSE 100 rose slightly to 10,888 points despite AstraZeneca shares dropping 7% due to merger talks with Bristol Myers Squibb, which face regulatory scrutiny. Shell agreed to sell its European onshore renewables business to TotalEnergies, reflecti...
AstraZeneca's shares fell 6% following reports of talks to acquire Bristol Myers Squibb, leaving analysts puzzled. Despite AstraZeneca's strong growth and innovation, brokers like Jefferies and UBS question the strategic timing and benefits of the de...
